| Valerie Ulstad, | |
|
701 Park Ave, O5, Minneapolis, MN 55415-1623 | |
| (612) 873-4105 | |
| Not Available |
| Full Name | Valerie Ulstad |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 701 Park Ave, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386686590 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 28832 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Valerie Ulstad, 701 Park Ave, Minneapolis, MN 55415-1623 Ph: () - | Valerie Ulstad, 701 Park Ave, O5, Minneapolis, MN 55415-1623 Ph: (612) 873-4105 |
News Archive
Researchers at the University of Calgary's Cumming School of Medicine (CSM) have for the first time been able to observe - live and in real-time - how the human body responds to often lethal fungal blood infections in the lung.
Significant advances in the neonatal intensive care have resulted in increased survival rates of children who are born at less than 26 weeks of gestation, so termed "extremely preterm children". Notably, however, improved survival rates have been accompanied by a higher risk for later cognitive, neuromotor, and sensory impairments in these children.
Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
This report notes that despite payments by drug and device companies, none of the more than 75 doctors named as participants were sanctioned.
In recent years, children's hospitals have joined in the national push to improve patient safety and avoid preventable problems. But it has been hard to measure progress, because of uncertainty about whether standard patient safety measurement tools apply to their patients, who are younger, smaller and on average sicker than those at other hospitals.
› Verified 5 days ago
Pascal Frino, M.D Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Veterans Dr, Minneapolis, MN 55417 Phone: 612-467-3183 | |
Dr. Ronald Alexander Reilkoff, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 612-672-7422 | |
Eugenia Shmidt, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 507-284-2511 | |
Daniel Tesfaye Kebed, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2450 Riverside Ave, Minneapolis, MN 55454 Phone: 612-672-6000 Fax: 612-273-4098 | |
Tenzin Yangchen, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2925 Chicago Ave, Minneapolis, MN 55407 Phone: 612-863-4000 Fax: 763-236-3026 | |
Shelley M Lennox, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 920 E 28th St, Suite 700, Minneapolis, MN 55407 Phone: 612-863-9062 Fax: 612-863-9252 | |
Dr. Markus Meyer, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2450 Riverside Ave, Minneapolis, MN 55454 Phone: 612-672-6000 |